I-Mab (IMAB) said the Center for Drug Evaluation of China National Medical Products Administration has accepted the company's IND application to initiate a phase 2 trial for enoblituzumab in combination with pembrolizumab in patients with selected solid tumors. The phase 2 trial will evaluate the efficacy of the combination of enoblituzumab and pembrolizumab.
I-Mab has in-licensed the rights to develop and commercialize enoblituzumab in Greater China from MacroGenics (MGNX).
Joan Shen, CEO of I-Mab, said: "We will be leveraging the data from clinical trials conducted by MacroGenics to advance the clinical development of enoblituzumab for approval in Greater China."
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.